 Samuel Ellis
Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 12 | 2024 | 3890 | 0.820 |
Why?
| | Blood Glucose | 8 | 2024 | 2327 | 0.740 |
Why?
| | Hypoglycemic Agents | 7 | 2024 | 1387 | 0.590 |
Why?
| | Hypoglycemia | 7 | 2024 | 477 | 0.570 |
Why?
| | Monitoring, Ambulatory | 2 | 2008 | 88 | 0.520 |
Why?
| | Insulin | 4 | 2014 | 2507 | 0.370 |
Why?
| | Diabetes Mellitus | 6 | 2012 | 1098 | 0.340 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2011 | 46 | 0.340 |
Why?
| | Comorbidity | 2 | 2015 | 1658 | 0.340 |
Why?
| | Pyrazines | 1 | 2011 | 92 | 0.330 |
Why?
| | Administration, Inhalation | 2 | 2014 | 574 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2016 | 2583 | 0.310 |
Why?
| | Triazoles | 1 | 2011 | 184 | 0.310 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2024 | 699 | 0.270 |
Why?
| | Pharmacists | 2 | 2000 | 240 | 0.270 |
Why?
| | Insulin Resistance | 1 | 2015 | 1241 | 0.250 |
Why?
| | Dried Blood Spot Testing | 2 | 2024 | 126 | 0.220 |
Why?
| | Drug Monitoring | 2 | 2024 | 395 | 0.200 |
Why?
| | Emtricitabine | 1 | 2024 | 205 | 0.190 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 276 | 0.190 |
Why?
| | Diabetic Nephropathies | 2 | 2018 | 318 | 0.180 |
Why?
| | Adenine | 1 | 2024 | 339 | 0.180 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2025 | 359 | 0.180 |
Why?
| | Obesity | 1 | 2015 | 3077 | 0.180 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 541 | 0.170 |
Why?
| | Heart Rate | 1 | 2025 | 855 | 0.160 |
Why?
| | Community Pharmacy Services | 2 | 2012 | 46 | 0.160 |
Why?
| | Hypolipidemic Agents | 1 | 2000 | 88 | 0.160 |
Why?
| | Bell Palsy | 1 | 1999 | 9 | 0.160 |
Why?
| | Hyperlipidemias | 1 | 2000 | 122 | 0.150 |
Why?
| | Pharmacy Service, Hospital | 1 | 2000 | 81 | 0.150 |
Why?
| | Students, Pharmacy | 2 | 2012 | 96 | 0.150 |
Why?
| | Treatment Refusal | 1 | 1999 | 98 | 0.150 |
Why?
| | Rural Health Services | 2 | 2012 | 141 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 47 | 0.130 |
Why?
| | Anti-HIV Agents | 1 | 2024 | 888 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 166 | 0.130 |
Why?
| | Counseling | 1 | 2000 | 408 | 0.120 |
Why?
| | Equipment Design | 2 | 2008 | 530 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2000 | 600 | 0.120 |
Why?
| | Humans | 26 | 2025 | 144759 | 0.110 |
Why?
| | Warfarin | 2 | 2007 | 170 | 0.110 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 760 | 0.110 |
Why?
| | Iohexol | 1 | 2014 | 23 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2014 | 157 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2018 | 576 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2025 | 2029 | 0.100 |
Why?
| | Cough | 1 | 2014 | 124 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 449 | 0.100 |
Why?
| | Pilot Projects | 3 | 2018 | 1886 | 0.090 |
Why?
| | Software | 2 | 2008 | 690 | 0.090 |
Why?
| | Sitagliptin Phosphate | 1 | 2011 | 31 | 0.090 |
Why?
| | Problem-Based Learning | 1 | 2012 | 98 | 0.080 |
Why?
| | Anticoagulants | 2 | 2007 | 722 | 0.080 |
Why?
| | Hypertension | 1 | 1999 | 1263 | 0.080 |
Why?
| | Postprandial Period | 1 | 2011 | 118 | 0.080 |
Why?
| | Female | 15 | 2025 | 78271 | 0.080 |
Why?
| | Male | 14 | 2025 | 72315 | 0.080 |
Why?
| | Education, Pharmacy | 1 | 2012 | 121 | 0.080 |
Why?
| | Plant Preparations | 1 | 2010 | 37 | 0.080 |
Why?
| | Adult | 10 | 2024 | 40449 | 0.080 |
Why?
| | Middle Aged | 9 | 2025 | 35875 | 0.080 |
Why?
| | Nonprescription Drugs | 1 | 2010 | 65 | 0.080 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 265 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2009 | 24 | 0.070 |
Why?
| | Hospitals, Veterans | 2 | 2000 | 259 | 0.070 |
Why?
| | HIV Infections | 1 | 2024 | 3154 | 0.070 |
Why?
| | Cross-Over Studies | 1 | 2011 | 601 | 0.070 |
Why?
| | Comparative Effectiveness Research | 1 | 2010 | 170 | 0.070 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 187 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1135 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 77 | 0.060 |
Why?
| | Physician's Role | 1 | 2009 | 218 | 0.060 |
Why?
| | Dental Care for Chronically Ill | 1 | 2007 | 10 | 0.060 |
Why?
| | Faculty, Dental | 1 | 2007 | 8 | 0.060 |
Why?
| | Nebulizers and Vaporizers | 1 | 2007 | 62 | 0.060 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 96 | 0.060 |
Why?
| | Long-Term Care | 1 | 2007 | 117 | 0.060 |
Why?
| | Biosensing Techniques | 1 | 2008 | 139 | 0.060 |
Why?
| | Education, Dental | 1 | 2007 | 35 | 0.060 |
Why?
| | Patient Care Team | 1 | 2012 | 689 | 0.060 |
Why?
| | Forecasting | 1 | 2007 | 391 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2925 | 0.060 |
Why?
| | Self Care | 1 | 2008 | 389 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 36 | 0.050 |
Why?
| | United States | 4 | 2011 | 15966 | 0.050 |
Why?
| | Hyperglycemia | 1 | 2008 | 375 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2168 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 145 | 0.050 |
Why?
| | Prevalence | 2 | 2008 | 2834 | 0.050 |
Why?
| | Alanine | 1 | 2024 | 171 | 0.050 |
Why?
| | Coronary Disease | 1 | 2006 | 383 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2025 | 250 | 0.050 |
Why?
| | Diabetes Complications | 3 | 2014 | 222 | 0.050 |
Why?
| | Homeostasis | 1 | 2007 | 640 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 164 | 0.050 |
Why?
| | Benchmarking | 1 | 2024 | 188 | 0.050 |
Why?
| | Activities of Daily Living | 1 | 2007 | 441 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 187 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2025 | 244 | 0.050 |
Why?
| | Data Collection | 2 | 2010 | 633 | 0.050 |
Why?
| | Circadian Rhythm | 1 | 2007 | 514 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1985 | 0.050 |
Why?
| | Tenofovir | 1 | 2024 | 295 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 651 | 0.040 |
Why?
| | Health Status | 1 | 2007 | 836 | 0.040 |
Why?
| | Patient Education as Topic | 2 | 2012 | 780 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 11679 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2000 | 119 | 0.040 |
Why?
| | Facial Nerve | 1 | 1999 | 39 | 0.040 |
Why?
| | Atrial Fibrillation | 1 | 2006 | 550 | 0.040 |
Why?
| | Pharmaceutical Services | 1 | 2000 | 78 | 0.040 |
Why?
| | Aged | 4 | 2025 | 25913 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 41 | 0.030 |
Why?
| | Risk Factors | 3 | 2006 | 10779 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2000 | 372 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 167 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 634 | 0.030 |
Why?
| | Depression | 1 | 2007 | 1558 | 0.030 |
Why?
| | Stroke | 1 | 2006 | 1256 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 561 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3162 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2947 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 506 | 0.030 |
Why?
| | Prospective Studies | 2 | 2010 | 7990 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 121 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2024 | 17066 | 0.020 |
Why?
| | Organizational Objectives | 1 | 2012 | 66 | 0.020 |
Why?
| | Medically Underserved Area | 1 | 2012 | 101 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2012 | 1414 | 0.020 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 197 | 0.020 |
Why?
| | Professional-Patient Relations | 1 | 2012 | 154 | 0.020 |
Why?
| | Databases, Factual | 2 | 2007 | 1486 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2000 | 5408 | 0.020 |
Why?
| | Computer Communication Networks | 1 | 2010 | 32 | 0.020 |
Why?
| | Perception | 1 | 2012 | 377 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2012 | 465 | 0.020 |
Why?
| | Time Factors | 1 | 2000 | 7173 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 948 | 0.020 |
Why?
| | Adolescent | 3 | 2014 | 22428 | 0.020 |
Why?
| | Fluoroquinolones | 1 | 2007 | 44 | 0.020 |
Why?
| | National Health Programs | 1 | 2006 | 23 | 0.020 |
Why?
| | International Normalized Ratio | 1 | 2006 | 49 | 0.010 |
Why?
| | Income | 1 | 2007 | 202 | 0.010 |
Why?
| | Monte Carlo Method | 1 | 2006 | 155 | 0.010 |
Why?
| | Models, Economic | 1 | 2006 | 62 | 0.010 |
Why?
| | Blood Pressure | 1 | 2012 | 1769 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2027 | 0.010 |
Why?
| | Surveys and Questionnaires | 2 | 2007 | 6048 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2012 | 1185 | 0.010 |
Why?
| | Clinical Competence | 1 | 2012 | 1244 | 0.010 |
Why?
| | Bayes Theorem | 1 | 2006 | 433 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2007 | 538 | 0.010 |
Why?
| | Health Care Costs | 1 | 2006 | 427 | 0.010 |
Why?
| | Colorado | 1 | 2012 | 4564 | 0.010 |
Why?
| | Biomarkers | 1 | 2012 | 4271 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1837 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1053 | 0.010 |
Why?
| | Primary Health Care | 1 | 2010 | 1733 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 14105 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3671 | 0.010 |
Why?
| | Infant | 1 | 2010 | 10034 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 11787 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2007 | 8265 | 0.010 |
Why?
| | Child | 1 | 2010 | 22633 | 0.000 |
Why?
|
|
Ellis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|